← All trials
NCT04487093
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 17, 2020
- Primary completion
- May 17, 2022
- Completion date
- Dec 1, 2022
- First posted
- Jul 27, 2020
- Last posted
- Jul 27, 2020
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- First Hospital of Shijiazhuang CityLead sponsor
- First Hospital of Shijiazhuang CityStudy chair
- First Hospital of Shijiazhuang CityReponsible party - principal investigator
- Government of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.